Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift)
Objectives To report the efficacy, safety and patient-reported outcome measures (PROs) of tofacitinib modified-release 11 mg once daily plus methotrexate in patients with rheumatoid arthritis (RA) from the open-label phase of Oral Rheumatoid Arthritis Trial (ORAL) Shift.Methods ORAL Shift was a glob...
Main Authors: | Boulos Haraoui, Janet Pope, Edward C Keystone, Eduardo Mysler, Tatjana Lukic, Harry Shi, Stanley B Cohen, Rebecca Germino, Lori Stockert, Annette Diehl, Sujatha Menon, Shixue Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-08-01
|
Series: | RMD Open |
Online Access: | https://rmdopen.bmj.com/content/7/2/e001673.full |
Similar Items
-
Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate
by: Alison O’Mahony, et al.
Published: (2018-06-01) -
Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy
by: Tsutomu Takeuchi, et al.
Published: (2021-08-01) -
Lipidic Liquid Crystalline Cubic Phases and Magnetocubosomes as Methotrexate Carriers
by: Monika Mierzwa, et al.
Published: (2019-04-01) -
Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open‐Label, Long‐Term Extension Studies up to 9.5 Years
by: Janet E. Pope, et al.
Published: (2019-04-01) -
Tofacitinib versus tocilizumab in the treatment of biological-naïve or previous biological-failure patients with methotrexate-refractory active rheumatoid arthritis
by: Yukitaka Ueki, et al.
Published: (2021-08-01)